|
|
|
|
|
Last Trade
|
Last Trade:
$0.24
|
Change:
-0.0191 (-7.32%)
|
Trade Time:
02:53 PM EST
|
Market Cap:
$5.94M
|
|
|
|
|
|
|
Description of Business
|
|
We are a clinical stage biopharmaceutical company targeting some of the greatest
unmet needs in oncology by developing differentiated and novel therapeutic
candidates together with our proprietary DRP® companion diagnostics in a
precision medicine approach. Our business strategy includes a focus on
leveraging our proprietary DRP® companion diagnostics platform to streamline the
drug development process and to identify patients that will benefit from
therapeutic candidates that other biotechnology or pharmaceutical companies have
abandoned or shelved after initiating clinical trials under an IND application
filed with the FDA, including candidates that have failed to achieve statistical
significance on the original endpoints established in their clinical trials.
|
|
|
|